The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-Alpha Reductase Inhibitors (5ARIs)

August 3, 2021Posted in5-Alpha Reductase Inhibitor (5ARI), PhD Studies, Select Publications, Student Studies, Venous Thromboembolism (VTE)
Journal: Clinical Epidemiology Authors: Olulade Ayodele, Howard J Cabral, David McManus, Susan Jick NLM Citation: Ayodele O, Cabral HJ, McManus D, Jick S. The Risk of Venous Thromboembolism (VTE) in Men with Benign…

CPRD Aurum database: Assessment of data quality and completeness of three important comorbidities

September 28, 2020Posted inRecent work examples, Select Publications, Validation Studies
Journal: Pharmacoepidemiology and Drug Safety Authors: Rebecca Persson, Catherine Vasilakis-Scaramozza, Katrina Wilcox Hagberg, Todd Sponholtz, Tim Williams, Puja Myles, Susan S Jick NML Citation: Persson R, Vasilakis-Scaramozza C, Hagberg KW, Sponholtz T, Williams T, Myles P,…

Proton-pump inhibitor use and myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink

May 31, 2020Posted inDrug Safety Studies, Recent student studies conducted at BCDSP, Safety of other important drugs, Select Publications, Student Studies
Journal: Epidemiology (Cambridge, MA) Authors: Yiran Qian, Susan Jick NLM Citation: Qian Y, Jick S. Proton-pump inhibitor use and myocardial infarction: a nested case-control study in the UK Clinical Practice Research…

Quality and completeness of diagnoses recorded in the new CPRD Aurum database: evaluation of pulmonary embolism

March 28, 2020Posted inRecent work examples, Select Publications, Validation Studies
Journal: Pharmacoepidemiology and Drug Safety Authors: Susan S Jick, Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Tim Williams, Elizabeth Crellin, Puja Myles NLM Citation: Jick SS, Hagberg KW, Persson R, Vasilakis-Scaramozza C, Williams T, Crellin E,…

The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database

March 25, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Journal of the American Academy of Dermatology Authors: Rebecca Persson, Katrina Wilcox Hagberg, Yiran Qian, Catherine Vasilakis-Scaramozza, Susan Jick NLM Citation: Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S. The risk…

The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

February 28, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Journal of the European Academy of Dermatology and Venereology Authors: C Vasilakis-Scaramozza, R Persson, K W Hagberg, S Jick NLM Citation: Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of…

Herpes zoster, hepatitis C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis

February 12, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Clinical Epidemiology Authors: Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Steve Niemcryk, Michael Peng, Maria Paris, Anders Lindholm, Susan Jick NLM Citation: Hagberg KW, Persson R, Vasilakis-Scaramozza C, Niemcryk S, Peng M, Paris M, Lindholm A,…